I don't consider them good financials due to the secondary, the recent loan and it's terms, and probably another secondary or loan setting up I'm guessing in about a year as they continue the buildout.
I consider good financials companies that generate cash - not eat it up. NXTM simply isn't there yet. Do they have enough cash to keep the doors open for a while - yes.
They have the FDA approved product - this will be hard to screw up. But it could be screwed up. And cash management should be the key thing.
I'm invested due to the potential - and the running start by having the approved product.
I still think it's a bit generous to call them good financials. I do have both long and trading shares. By the time I consider the financials to be in good shape other folks will have 'discovered' this company, a good bit of the run will be over, and I probably will have sold most of my shares.
At the last Piper Jaffray health care conference Nxstage management made comments that the 50 million dollar loan should take them through to a cash flow positive state.
I'm really hoping (praying maybe..lol) the company can buildout without another secondary.
Davebugs, you have been following Nxstage for awhile and your posts seem smart and informed. If you don't mind me asking do you have a target price in mind for selling your shares? What number of patients do you think Nxstage can realistically acquire?